Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9099
Title: Long COVID: An inevitable sequela of SARS-CoV-2 infection
Authors: Chih-Cheng Lai
Muh-Yong Yen
Ping-Ing Lee
Wen-Chien Ko
Chi-Kuei Hsu
Po-Ren Hsueh
Keywords: COVID-19
Long COVID
Post-acute COVID
SARS-CoV-2
Vaccine
Issue Date: Jul-2024
Publisher: Journal of Microbiology, Immunology and Infection
Citation: Riview Article
Abstract: At present, there are more than 560 million confirmed cases of the coronavirus disease 2019 (COVID-19) worldwide. Although more than 98% of patients with severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection can survive acute COVID, a significant portion of survivors can develop residual health problems, which is termed as long COVID. Although severe COVID-19 is generally associated with a high risk of long COVID, patients with asymptomatic or mild disease can also show long COVID. The definition of long COVID is inconsistent and its clinical manifestations are protean. In addition to general symptoms, such as fatigue, long COVID can affect many organ systems, including the respiratory, neurological, psychosocial, cardiovascular, gastrointestinal, and metabolic systems. Moreover, patients with long COVID may experience exercise intolerance and impaired daily function and quality of life. Long COVID may be caused by SARS-CoV-2 direct injury or its associated immune/inflammatory response. Assessment of patients with long COVID requires comprehensive evaluation, including history taking, physical examination, laboratory tests, radiography, and functional tests. However, there is no known effective treatment for long COVID. Based on the limited evidence, vaccines may help to prevent the development of long COVID. As long COVID is a new clinical entity that is constantly evolving, there are still many unknowns, and further investigation is warranted to enhance our understanding of this disease.
URI: http://localhost:8080/xmlui/handle/123456789/9099
Appears in Collections:VOL 56 NO 1 2023

Files in This Item:
File Description SizeFormat 
1-9.pdf482.48 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.